K
Kristin R. Swanson
Researcher at Mayo Clinic
Publications - 191
Citations - 9116
Kristin R. Swanson is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Glioma & Magnetic resonance imaging. The author has an hindex of 47, co-authored 183 publications receiving 7761 citations. Previous affiliations of Kristin R. Swanson include University of Washington & Arizona's Public Universities.
Papers
More filters
Posted ContentDOI
Morphological Metrics of Magnetic Resonance Imaging of Glioblastoma as Biomarkers of Prognosis
TL;DR: In this article, the authors computed fractal dimension and lacunarity measures for glioblastoma-induced abnormalities on gadolinium-enhanced T1-weighted magnetic resonance imaging (T1Gd MRI) and fluid-attenuated inversion recovery (FLAIR) MRIs.
Journal ArticleDOI
Tmod-13. simulating patterns of recurrence following ischemia in brain tumors
Lee Curtin,Andrea Hawkins-Daarud,Alyx B. Porter,Joshua J. Jacobs,Markus R. Owen,Kristoffer G. van der Zee,Rami James N. Aoun,Bernard R. Bendok,Kristin R. Swanson +8 more
TL;DR: The role of angiogenesis in malignant progression of gliomas is quantified in silico modeling integrates imaging and histology, and hypoxia has been seen to drive infiltrative growth ofglioma cells, but its clinical effects are not well understood.
Women's Health and Women's Health Care: Recommendations of the 1996 AAN Expert Panel on Women's Health Writing Group of the 1996 AAN Expert Panel on Women's Health*
Catherine Ingram Fogel,Marcia Killien,Lucy N. Marion,Angela Barron McBride,Joan L. F. Shaver,Kristin R. Swanson,Dianna Taylor,Nancy Fugate Woods +7 more
TL;DR: The Expert Panel on Women's Health of the American Academy of Nursing has studied the need for transformative change in women's health services and provides recommendations to facilitate such change in the current system of health care and in nursing education, practice, and policy.
Posted ContentDOI
Quantifying glioblastoma drug penetrance from experimental data
TL;DR: Mathematically modeling the dynamics of therapeutic response in patient–derived xenografts (PDX) and fitting the mathematical model to bioluminescence imaging flux data may be able to assess the degree to which both drug resistance and drug penetrance are driving varied responses to these therapies.
Journal ArticleDOI
Prostate-specific antigen
TL;DR: ICD-10 CODE DESCRIPTION C61 Malignant neoplasm of prostate C67.5 MalignantNeoplasms of bladder neck C77.4 Secondary and unspecified malignant neoperasm of inguinal and lower limb lymph nodes C 77.5 secondary and unspecifiedmalignant neplasm of intrapelvic lymph nodes of multiple regions C79.51 Secondary malignant Neoplasm